Mesoblast (NASDAQ:MESO) Shares Down 5.5% – Here’s Why

Mesoblast Limited (NASDAQ:MESO)’s share price fell 5.5% during trading on Thursday . The stock traded as low as $14.85 and last traded at $14.9350. 50,806 shares traded hands during mid-day trading, a decline of 80% from the average session volume of 254,950 shares. The stock had previously closed at $15.80.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mesoblast in a research report on Thursday, January 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold”.

Mesoblast Price Performance

The stock has a fifty day moving average of $16.19 and a 200 day moving average of $16.88. The stock has a market cap of $1.91 billion, a price-to-earnings ratio of -16.83 and a beta of 2.19. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.58 and a quick ratio of 1.41.

Mesoblast (NASDAQ:MESO) last posted its quarterly earnings results on Thursday, January 29th. The company reported ($0.16) earnings per share (EPS) for the quarter. The business had revenue of $25.67 million for the quarter. On average, analysts expect that Mesoblast Limited will post -0.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Mesoblast

Several hedge funds have recently added to or reduced their stakes in MESO. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Mesoblast by 30.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,383 shares of the company’s stock worth $43,000 after buying an additional 558 shares during the period. Vanguard Personalized Indexing Management LLC grew its stake in Mesoblast by 5.4% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 14,047 shares of the company’s stock valued at $226,000 after acquiring an additional 716 shares during the period. JPMorgan Chase & Co. increased its holdings in Mesoblast by 55.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 2,831 shares of the company’s stock worth $46,000 after acquiring an additional 1,012 shares in the last quarter. Choreo LLC raised its position in Mesoblast by 15.1% during the fourth quarter. Choreo LLC now owns 12,225 shares of the company’s stock worth $227,000 after acquiring an additional 1,600 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new position in Mesoblast during the fourth quarter worth $32,000. 1.43% of the stock is owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.